zuma-1: 3-year follow-up on axi-cel in lbcl patients
Published 3 years ago • 75 plays • Length 1:41Download video MP4
Download video MP3
Similar videos
-
2:06
car-t in dlbcl: 4-year follow-up data from zuma-1
-
0:54
insights into the zuma-23 trial: axi-cel in frontline high-risk lbcl
-
2:59
axi-cel in older patients: data from zuma-1 and clinical use
-
2:19
zuma-3: identifying the optimal dose of axi-cel in r/r all
-
1:08
zuma-7: overall survival benefit of axi-cel over soc in second-line lbcl
-
15:07
introduction to neonatal jaundice
-
5:09
what is gemba walk? @pharmaven #gemba #manufacturing #usfda #leadership #pharma #excellence #gmp
-
3:47
polatuzumab vedotin in patients with lbcl who have relapsed after car-t therapy
-
1:34
zuma-1 update: safety data of axi-cel in patients with r/r dlbcl
-
2:43
long-term follow-up results of zuma-5: axi-cel in patients with r/r indolent nhl
-
2:32
zuma-1 update: durable survival in r/r dlbcl patients treated with axi-cel
-
1:15
primary overall survival analysis of the zuma-7 trial
-
4:44
zuma-7 subgroup analysis: axi-cel vs soc in elderly patients with r/r lbcl
-
2:52
zuma-24 preliminary analysis of axi-cel in the outpatient setting in patients with r/r lbcl
-
0:54
zuma-3 end of phase i results: axi-cel for r/r all
-
2:17
zuma-12: axicabtagene ciloleucel as a first-line therapy in patients with high-risk lbcl
-
6:37
zuma-7: axi-cel in r/r large b-cell lymphoma
-
3:32
zuma-1: updated data and future prospects
-
2:48
zuma-1: safety and efficacy of axicabtagene in refractory non-hodgkin lymphoma patients
-
2:24
zuma-1: a pivotal trial of axicabtagene ciloleucel (axi-cel; kte-c19) in patients with nhl
-
3:49
zuma-3: impact of prior blinatumomab and allosct
-
2:06
zuma-12: axi-cel as first-line therapy in high-risk large b-cell lymphoma